Telegraph -- Six to 11-year-olds will not be given Xolair, under draft guidance issued on Wednesday by the National Institute for Health and Clinical Excellence (Nice). Nice said Xolair’s high cost did not justify its “little extra benefit compared with existing treatments”.
